Tobacco Control

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hughes, J R
Right arrow Articles by Callas, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hughes, J R
Right arrow Articles by Callas, P
Tobacco Control 2004;13:175-179
© 2004 BMJ Publishing Group Ltd


RESEARCH PAPER

Smoking behaviour and toxin exposure during six weeks use of a potential reduced exposure product: Omni

J R Hughes1, S S Hecht2, S G Carmella2, S E Murphy2, P Callas3

1 University of Vermont, Departments of Psychiatry, Psychology and Family Practice, Burlington, Vermont, USA
2 University of Minnesota Cancer Center, Minneapolis, Minnesota, USA
3 University of Vermont, Biometry Facility, Burlington, Vermont, USA

Correspondence to:
John R Hughes MD
University of Vermont, Departments of Psychiatry, Psychology and Family Practice, 38 Fletcher Place, Burlington, VT 05401-1419, USA; john.hughes{at}uvm.edu

Objective: To determine smoking behaviour, acceptability, and toxin exposure when smokers switch to the potential reduced exposure product—Omni cigarette.

Design: 12 week randomised, crossover study of Omni versus own cigarettes.

Participants: 19 light/ultralight and 15 regular smokers.

Outcomes: Cigarettes/day, smoking topography, craving, withdrawal symptoms, urinary cotinine plus its glucuronide (total cotinine), nicotine plus its glucuronide (total nicotine), and carcinogen metabolites (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol plus its glucuronides and 1-hydroxypyrene).

Results: When switched to Omni, smokers smoked the same number of cigarettes/day, smoked Omni cigarettes less intensely (total puff volume = –11%) and had slightly lower total cotinine (–18%) levels than their own cigarettes, but had a slightly greater carbon monoxide boost/cig (+21%). Craving and withdrawal ratings were similar with Omni and own cigarettes. Carcinogen metabolite levels were somewhat but not significantly lower with Omni. About half of smokers rated Omni as better for their health and about two thirds stated it was weaker and worse tasting than their own cigarettes.

Conclusions: Although Omni may be an adequate behavioural and pharmacological substitute for traditional cigarettes, it may not decrease carcinogen exposure and may increase carbon monoxide. Replications with larger sample sizes and longer follow up are needed. These results indicate the need for regulation of reduced exposure and reduced risk claims.


Abbreviations: CO, carbon monoxide; 1-HOP, 1-hydroxypyrene; IVR, interactive voice recording; PAH, polycyclic aromatic hydrocarbons; PREP, potential reduced exposure product; NIH, National Institutes of Health; NNAL, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides; TSNA, tobacco specific nitrosamines

Keywords: carcinogens; harm reduction; nicotine; Omni; risk reduction; potential reduced exposure product




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. F. Pankow, K. H. Watanabe, P. L. Toccalino, W. Luo, and D. F. Austin
Calculated Cancer Risks for Conventional and "Potentially Reduced Exposure Product" Cigarettes
Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 584 - 592.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
D. Hammond, G. T. Fong, K. M. Cummings, and A. Hyland
Smoking Topography, Brand Switching, and Nicotine Delivery: Results from an In vivo Study
Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1370 - 1375.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 by the BMJ Publishing Group Ltd.